AstraZeneca’s coronavirus vaccine was approved by Canadian regulators on Friday for all adults

Spread the News


AstraZeneca’s coronavirus vaccine was approved by Canadian regulators on Friday for all adults

Following those from Pfizer and Moderna, it is the third COVID-19 vaccine given to greenlight by Canada. AstraZeneca’s coronavirus vaccine was approved by Canadian regulators on Friday for all adults. Following those from Pfizer and Moderna, it is the third COVID-19 vaccine given to greenlight by Canada.

This is something that is really positive. It means more people are vaccinated, and earlier, Prime Minister Justin Trudeau said, adding that a nation of 38 million people will now receive a total of 6.5 million vaccinations by the end of March, with a new approval of 5,000 more now.

Health Canada approved the AstraZeneca vaccine for people aged 18 and up, expressing faith that it will work for the elderly, despite the fact that some nations, such as France, have only approved it for people aged 18 to 65, citing a lack of evidence that it works in older adults.

The vaccine appears to provide less safety than those already approved, with studies showing approximately 62 percent efficacy, but experts have said any vaccine with an efficacy rate of over 50 percent could help stop the outbreak. It’s a viable choice, according to Health Canada’s chief medical advisor, Dr. Supriya Sharma.

According to Ms. Sharma, no one has died or been seriously ill in trials of the vaccines that have been approved by Canada, as well as those of Johnson & Johnson and Novavax shots that will be approved soon.

Health officials in Germany and other countries have expressed concerns that AstraZeneca has not tested enough elderly people for the vaccine to show that it works for them and have suggested that it would not be approved for people over 65 years of age. It was only approved by Belgium for people 55 and under Health Canada reported that its decision was based on pooled analyses from four ongoing trials in clinical research, as well as evidence from countries where it was licensed.

According to Health Canada, the benefit-risk profile of the AstraZeneca COVID-19 vaccine is positive for the proposed indication in adults 18 years and older based on the totality of the details.

We’re beginning to see evidence in the real world. According to Ms. Sharma, there is evidence that it will be successful in the older age group.

Canada has placed an order for 22 million doses of the AstraZeneca vaccine, which was co-developed by University of Oxford researchers. By the end of June, it will also receive up to 1.9 million doses through COVAX, a global vaccine-sharing programme.

Mr. Trudeau said that two million of those doses would come from India’s Serum Institute, which Ms. Sharma said uses the same formula but a slightly different methodology and was also accepted.

More than 50 countries have already approved the AstraZeneca vaccine. It’s less costly and simpler to manage than the Pfizer-BioNTech vaccine, which includes deep-freeze storage, which isn’t available in many developing countries. Both vaccinations, given weeks apart, require two shots per person.

Many European countries, including Canada, have failed to vaccinate citizens as easily as the United Kingdom, Israel, the United States, and other countries. Canada lacks domestic production, and Mr. Trudeau’s government has been chastised for not acquiring vaccines quickly enough, despite ordering enough doses to supply the country’s population ten times over.

The AstraZeneca vaccine makes up the majority of COVAX’s stockpile, and an early study recently raised fears that it may not be effective in preventing mild and moderate disease caused by the variant first seen in South Africa. South Africa scaled back its scheduled rollout of the AstraZeneca vaccine last week, opting instead for its health care staff to use an unlicensed shot from Johnson & Johnson.


Spread the News

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: